These findings are consistent with previous observations of trastuzumab improving vascular perfusion [18,36] and tumor oxygenation [35,37] in preclinical models of HER2+ breast cancer, and demonstrate that alterations in the percent tumor volume of the LV-HC habitat may be an early indicator of trastuzumab response. This evidence concerns the gene ERBB2 and breast cancer.